-
2
-
-
1842510682
-
Trials, tribulations and trends in tumor modeling in mice
-
Schuh JCL (2004) Trials, tribulations and trends in tumor modeling in mice. Toxicol Pathol 32 (Suppl 1): 53-66
-
(2004)
Toxicol Pathol
, vol.32
, Issue.SUPPL. 1
, pp. 53-66
-
-
Schuh, J.C.L.1
-
3
-
-
0022399581
-
Tyrosine kinase receptor with extensive homology to EGF receptor shares chrmosomal location with neu oncogene
-
Coussens L, Yang-Feng TC, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Lieberman TA, Schlessinger J, Francke U et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chrmosomal location with neu oncogene. Science 230: 1132-1139
-
(1985)
Science
, vol.230
, pp. 1132-1139
-
-
Coussens, L.1
Yang-Feng, T.C.2
Liao, Y.C.3
Chen, E.4
Gray, A.5
McGrath, J.6
Seeburg, P.H.7
Lieberman, T.A.8
Schlessinger, J.9
Francke, U.10
-
4
-
-
0031550257
-
Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells
-
Pirollo KF, Hao Z, Rait A (1997) Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. Biochem Biophys Res Commun 230: 196-201
-
(1997)
Biochem Biophys Res Commun
, vol.230
, pp. 196-201
-
-
Pirollo, K.F.1
Hao, Z.2
Rait, A.3
-
5
-
-
0033559619
-
Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
-
Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ (1999) Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59: 1347-1355
-
(1999)
Cancer Res
, vol.59
, pp. 1347-1355
-
-
Pietras, R.J.1
Poen, J.C.2
Gallardo, D.3
Wongvipat, P.N.4
Lee, H.J.5
Slamon, D.J.6
-
6
-
-
0034234854
-
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-CBL and enhancing ubiquitination of HER-2
-
Klapper LN, Waterman H, Sela M, Yarden Y (2000) Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-CBL and enhancing ubiquitination of HER-2. Cancer Res 60: 3384-3388
-
(2000)
Cancer Res
, vol.60
, pp. 3384-3388
-
-
Klapper, L.N.1
Waterman, H.2
Sela, M.3
Yarden, Y.4
-
7
-
-
0032851961
-
Non-clinical studies addressing the mechanism of action of Trastuzumab (Herceptin)
-
Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA (1999) Non-clinical studies addressing the mechanism of action of Trastuzumab (Herceptin). Semin Oncol 26 (Suppl 12): 60-70
-
(1999)
Semin Oncol
, vol.26
, Issue.SUPPL. 12
, pp. 60-70
-
-
Sliwkowski, M.X.1
Lofgren, J.A.2
Lewis, G.D.3
Hotaling, T.E.4
Fendly, B.M.5
Fox, J.A.6
-
8
-
-
0001223491
-
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo
-
Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Am J Pathol 151: 1523-1530
-
(1997)
Am J Pathol
, vol.151
, pp. 1523-1530
-
-
Petit, A.M.1
Rak, J.2
Hung, M.C.3
Rockwell, P.4
Goldstein, N.5
Fendly, B.6
Kerbel, R.S.7
-
9
-
-
0034076307
-
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
-
Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6: 443-446
-
(2000)
Nat Med
, vol.6
, pp. 443-446
-
-
Clynes, R.A.1
Towers, T.L.2
Presta, L.G.3
Ravetch, J.V.4
-
10
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, Levin W, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
Levin, W.4
Ullrich, A.5
McGuire, W.L.6
-
11
-
-
0024337144
-
Studies of the HER-2/neu proto-oncogene in human breast cancer and ovarian cancer
-
Slamon DJ, Godolphin W, Jones L, Holt J, Wong S, Keith D, Levin W, Stuart S, Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast cancer and ovarian cancer. Science 244: 707-712
-
(1989)
Science
, vol.244
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.3
Holt, J.4
Wong, S.5
Keith, D.6
Levin, W.7
Stuart, S.8
Udove, J.9
Ullrich, A.10
-
12
-
-
0001261042
-
Studies of the HER-2/neu oncogene in human breast cancer
-
Slamon D, Press M, Godolphin W, Ramos L, Haran P, Shek L, Stuart S, Ullrich A (1989) Studies of the HER-2/neu oncogene in human breast cancer. Cancer Cells 7: 371-379
-
(1989)
Cancer Cells
, vol.7
, pp. 371-379
-
-
Slamon, D.1
Press, M.2
Godolphin, W.3
Ramos, L.4
Haran, P.5
Shek, L.6
Stuart, S.7
Ullrich, A.8
-
13
-
-
0031034106
-
HER-2/neu signal transduction in human breast and ovarian cancer
-
Reese D, Slamon D (1997) HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 15: 1-8
-
(1997)
Stem Cells
, vol.15
, pp. 1-8
-
-
Reese, D.1
Slamon, D.2
-
14
-
-
0023196582
-
erbB2 is a potent oncogene when expressed in NIH-3T3 cells
-
DiFiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA (1987) erbB2 is a potent oncogene when expressed in NIH-3T3 cells. Science 237: 178-181
-
(1987)
Science
, vol.237
, pp. 178-181
-
-
DiFiore, P.P.1
Pierce, J.H.2
Kraus, M.H.3
Segatto, O.4
King, C.R.5
Aaronson, S.A.6
-
15
-
-
0023430930
-
Increased expression of the putative growth factor receptor p185HER-2 causes transformation and tumorigenesis of NIH-3T3 cells
-
Hudziak RM, Schlessinger J, Ullrich A (1987) Increased expression of the putative growth factor receptor p185HER-2 causes transformation and tumorigenesis of NIH-3T3 cells. Proc Natl Acad Sci USA 84: 7159-7163
-
(1987)
Proc Natl Acad Sci USA
, vol.84
, pp. 7159-7163
-
-
Hudziak, R.M.1
Schlessinger, J.2
Ullrich, A.3
-
16
-
-
0026739541
-
Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor
-
Chazin V, Kaleko M, Miller A, Slamon DJ (1992) Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7: 1859-1865
-
(1992)
Oncogene
, vol.7
, pp. 1859-1865
-
-
Chazin, V.1
Kaleko, M.2
Miller, A.3
Slamon, D.J.4
-
17
-
-
0025883759
-
Oncogenic potential of erbB-2 in human mammary epithelial cells
-
Pierce J, Arnstein P, Dimarco E, Artrip J, Kraus M, Lonardo F, Di Fiore P, Aaronson S (1991) Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 6: 1189-1194
-
(1991)
Oncogene
, vol.6
, pp. 1189-1194
-
-
Pierce, J.1
Arnstein, P.2
Dimarco, E.3
Artrip, J.4
Kraus, M.5
Lonardo, F.6
Di Fiore, P.7
Aaronson, S.8
-
18
-
-
0030870295
-
The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
-
Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ (1997) The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15: 537-547
-
(1997)
Oncogene
, vol.15
, pp. 537-547
-
-
Pegram, M.D.1
Finn, R.S.2
Arzoo, K.3
Beryt, M.4
Pietras, R.J.5
Slamon, D.J.6
-
19
-
-
0032578797
-
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
-
Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ (1998) Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17: 2235-2249
-
(1998)
Oncogene
, vol.17
, pp. 2235-2249
-
-
Pietras, R.J.1
Pegram, M.D.2
Finn, R.S.3
Maneval, D.A.4
Slamon, D.J.5
-
20
-
-
0032445260
-
HER-2/neu as a predictive marker of response to breast cancer therapy
-
Pegram MD, Pauletti G, Slamon DJ (1998) HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52: 65-77
-
(1998)
Breast Cancer Res Treat
, vol.52
, pp. 65-77
-
-
Pegram, M.D.1
Pauletti, G.2
Slamon, D.J.3
-
21
-
-
0033118889
-
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
-
Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241-2251
-
(1999)
Oncogene
, vol.18
, pp. 2241-2251
-
-
Pegram, M.1
Hsu, S.2
Lewis, G.3
Pietras, R.4
Beryt, M.5
Sliwkowski, M.6
Coombs, D.7
Baly, D.8
Kabbinavar, F.9
Slamon, D.10
-
22
-
-
0032713438
-
The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression
-
Xu F, Yu Y, Le X-F, Boyer C, Mills GB, Bast RC (1999) The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 5: 3653-3660
-
(1999)
Clin Cancer Res
, vol.5
, pp. 3653-3660
-
-
Xu, F.1
Yu, Y.2
Le, X.-F.3
Boyer, C.4
Mills, G.B.5
Bast, R.C.6
-
23
-
-
12144291334
-
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients
-
Konecny GE, Meng YG, Untch M, Wang H-J, Bauerfeind I, Epstein M, Stieber P, Vernes J-M, Gutierrez J, Hong K et al (2004) Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10: 1706-1716
-
(2004)
Clin Cancer Res
, vol.10
, pp. 1706-1716
-
-
Konecny, G.E.1
Meng, Y.G.2
Untch, M.3
Wang, H.-J.4
Bauerfeind, I.5
Epstein, M.6
Stieber, P.7
Vernes, J.-M.8
Gutierrez, J.9
Hong, K.10
-
24
-
-
11144354140
-
Molecular therapeutics: Promise and challenges
-
Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H, Smith DL, Meric-Bernstam F, Hortobagyi GN, Mills GB (2004) Molecular therapeutics: promise and challenges. Semin Oncol 31: 39-53
-
(2004)
Semin Oncol
, vol.31
, pp. 39-53
-
-
Kohn, E.C.1
Lu, Y.2
Wang, H.3
Yu, Q.4
Yu, S.5
Hall, H.6
Smith, D.L.7
Meric-Bernstam, F.8
Hortobagyi, G.N.9
Mills, G.B.10
-
25
-
-
0043238709
-
Combined modality management of breast cancer: Development of predictive markers through proteomics
-
Chakravarthy B, Pietenpol JA (2003) Combined modality management of breast cancer: development of predictive markers through proteomics. Semin Oncol 30: 23-36
-
(2003)
Semin Oncol
, vol.30
, pp. 23-36
-
-
Chakravarthy, B.1
Pietenpol, J.A.2
-
26
-
-
0037662222
-
Clinical applications of proteomics
-
Petricoin EF, Liotta LA (2003) Clinical applications of proteomics. J Nutr 133: 2476S-2484S
-
(2003)
J Nutr
, vol.133
-
-
Petricoin, E.F.1
Liotta, L.A.2
-
27
-
-
0038004636
-
Clinical biomarkers in drug discovery and development
-
Frank R, Hargreaves R (2003) Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2: 566-580
-
(2003)
Nat Rev Drug Discov
, vol.2
, pp. 566-580
-
-
Frank, R.1
Hargreaves, R.2
-
28
-
-
1442283808
-
Emerging treatments in oncology: Focus on tyrosine kinase (erbB) receptor inhibitors
-
Hamid O (2004) Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors. J Am Pharm Assoc 44: 52-58
-
(2004)
J Am Pharm Assoc
, vol.44
, pp. 52-58
-
-
Hamid, O.1
-
29
-
-
0035431318
-
Scoring a bull's-eye against cancer genome targets
-
Workman P (2001) Scoring a bull's-eye against cancer genome targets. Curr Opin Pharmacol 1: 342-352
-
(2001)
Curr Opin Pharmacol
, vol.1
, pp. 342-352
-
-
Workman, P.1
-
30
-
-
0034905925
-
Signal transduction: Multiple pathways, multiple options for therapy
-
Heldin CH (2001). Signal transduction: multiple pathways, multiple options for therapy. Stem Cells 19: 295-303
-
(2001)
Stem Cells
, vol.19
, pp. 295-303
-
-
Heldin, C.H.1
-
31
-
-
0035215722
-
Selected novel anticancer treatments targeting cell signaling proteins
-
Elsayed YA, Sausville EA (2001) Selected novel anticancer treatments targeting cell signaling proteins. Oncologists 6: 517-537
-
(2001)
Oncologists
, vol.6
, pp. 517-537
-
-
Elsayed, Y.A.1
Sausville, E.A.2
-
32
-
-
0035489608
-
Proteomics of breast cancer for marker discovery and signal pathway profiling
-
Hondermarck H, Vercoutter-Edouart AS, Revillion F, Lemoine J, er-Yazidi-Belkoura I, Nurcombe V, Peyrat JP (2001) Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 1: 1216-1232
-
(2001)
Proteomics
, vol.1
, pp. 1216-1232
-
-
Hondermarck, H.1
Vercoutter-Edouart, A.S.2
Revillion, F.3
Lemoine, J.4
Er-Yazidi-Belkoura, I.5
Nurcombe, V.6
Peyrat, J.P.7
-
33
-
-
0036121207
-
Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer
-
Arteaga CL, Khuri F, Krystal G, Sebti S (2002) Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Semin Oncol 29 (1 suppl 4): 15-26
-
(2002)
Semin Oncol
, vol.29
, Issue.1 SUPPL. 4
, pp. 15-26
-
-
Arteaga, C.L.1
Khuri, F.2
Krystal, G.3
Sebti, S.4
-
34
-
-
0035496104
-
APC, signal transduction and genetic instability in colorectal cancer
-
Fodde R, Smits R, Clevers H (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1: 55-67
-
(2001)
Nat Rev Cancer
, vol.1
, pp. 55-67
-
-
Fodde, R.1
Smits, R.2
Clevers, H.3
-
35
-
-
0036479998
-
Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma
-
Graff JR (2002) Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma. Exp Opin Ther Targets 6: 103-113
-
(2002)
Exp Opin Ther Targets
, vol.6
, pp. 103-113
-
-
Graff, J.R.1
-
36
-
-
0035026164
-
Targeting growth factor receptors: Integration of novel therapeutics in the management of head and neck cancer
-
Lango MN, Shin DM, Grandis JR (2001) Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer. Curr Opin Oncol 13: 168-175
-
(2001)
Curr Opin Oncol
, vol.13
, pp. 168-175
-
-
Lango, M.N.1
Shin, D.M.2
Grandis, J.R.3
-
37
-
-
0034334115
-
Signal transduction pathways: Targets for chemoprevention of skin cancer
-
Bode AM, Dong Z (2000) Signal transduction pathways: targets for chemoprevention of skin cancer. Lancet Oncol 1: 181-188
-
(2000)
Lancet Oncol
, vol.1
, pp. 181-188
-
-
Bode, A.M.1
Dong, Z.2
-
38
-
-
0034961691
-
Angiogenesis and antiangiogenic approaches to sarcomas
-
Heymach JV (2001) Angiogenesis and antiangiogenic approaches to sarcomas. Curr Opin Oncology 13: 261-269
-
(2001)
Curr Opin Oncology
, vol.13
, pp. 261-269
-
-
Heymach, J.V.1
-
39
-
-
0035409376
-
Signaling pathways in pancreatic cancer
-
Reddy SA (2001) Signaling pathways in pancreatic cancer. Cancer J 7: 274-286
-
(2001)
Cancer J
, vol.7
, pp. 274-286
-
-
Reddy, S.A.1
-
41
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186
-
(1971)
N Engl J Med
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
42
-
-
0842289982
-
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy
-
Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Triani T, Melisi D, De Vita F, De Placido S, Bianco AR et al (2004) Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10: 784-793
-
(2004)
Clin Cancer Res
, vol.10
, pp. 784-793
-
-
Ciardiello, F.1
Bianco, R.2
Caputo, R.3
Caputo, R.4
Damiano, V.5
Triani, T.6
Melisi, D.7
De Vita, F.8
De Placido, S.9
Bianco, A.R.10
-
43
-
-
4143076078
-
Targeting the epidermal growth factor receptor
-
El-Rayes BF, LoRusso PM (2004) Targeting the epidermal growth factor receptor. Br J Cancer 91: 418-424
-
(2004)
Br J Cancer
, vol.91
, pp. 418-424
-
-
El-Rayes, B.F.1
LoRusso, P.M.2
-
44
-
-
2342492317
-
Review of epidermal growth factor receptor biology
-
Herbst RS (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59 (2 suppl): 21-26
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.59
, Issue.2 SUPPL.
, pp. 21-26
-
-
Herbst, R.S.1
-
45
-
-
0030018743
-
Systems approach to cancer therapy (antiangiogenics + standard cytotoxics - mechanism(s) of interaction)
-
Teicher BA (1996) Systems approach to cancer therapy (antiangiogenics + standard cytotoxics - mechanism(s) of interaction). Cancer Metastasis Rev 15: 247-272
-
(1996)
Cancer Metastasis Rev
, vol.15
, pp. 247-272
-
-
Teicher, B.A.1
-
47
-
-
0034789517
-
Receptor tyrosine signaling as a target for cancer intervention strategies
-
Zwick E, Bange J, Ullrich A (2001) Receptor tyrosine signaling as a target for cancer intervention strategies. Endocr Relat Cancer 8: 161-173
-
(2001)
Endocr Relat Cancer
, vol.8
, pp. 161-173
-
-
Zwick, E.1
Bange, J.2
Ullrich, A.3
-
48
-
-
0034799139
-
A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
-
Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958-2970
-
(2001)
Clin Cancer Res
, vol.7
, pp. 2958-2970
-
-
Ciardiello, F.1
Tortora, G.2
-
49
-
-
0034048844
-
Kinase inhibitors in cancer therapy. A look ahead
-
Sedlacek HH (2000) Kinase inhibitors in cancer therapy. A look ahead. Drugs 59: 435-476
-
(2000)
Drugs
, vol.59
, pp. 435-476
-
-
Sedlacek, H.H.1
-
50
-
-
0031961980
-
Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor
-
Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ (1998) Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273: 200-206
-
(1998)
J Biol Chem
, vol.273
, pp. 200-206
-
-
Moscatello, D.K.1
Holgado-Madruga, M.2
Emlet, D.R.3
Montgomery, R.B.4
Wong, A.J.5
-
51
-
-
0037229076
-
Targeting the epidermal growth factor receptor in cancer: Apoptosis takes center stage
-
Kari C, Chan TO, de Quadros MR, Roderick U (2003) Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 63: 1-5
-
(2003)
Cancer Res
, vol.63
, pp. 1-5
-
-
Kari, C.1
Chan, T.O.2
De Quadros, M.R.3
Roderick, U.4
-
52
-
-
3442891161
-
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor
-
Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM (2004) Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64: 5355-5362
-
(2004)
Cancer Res
, vol.64
, pp. 5355-5362
-
-
Huang, S.1
Armstrong, E.A.2
Benavente, S.3
Chinnaiyan, P.4
Harari, P.M.5
-
53
-
-
2342611980
-
Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small cell ling cancer
-
Kim DW, Choy H (2004) Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small cell ling cancer. Int J Radiat Oncol Biol Phys 59 (2 suppl): 11-20
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.59
, Issue.2 SUPPL.
, pp. 11-20
-
-
Kim, D.W.1
Choy, H.2
-
54
-
-
26044440518
-
Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors in combined-modality therapy for non-small cell lung cancer
-
Thomas SM, Grandis JR (2004) Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors in combined-modality therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 59 (2 suppl): 11-20
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.59
, Issue.2 SUPPL.
, pp. 11-20
-
-
Thomas, S.M.1
Grandis, J.R.2
-
55
-
-
0842330212
-
Combining EGFR inhibitors with radiation or chemotherapy: Will preclinical studies predict clinical results?
-
Harari PM, Huang SM (2004) Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results? Int J Radiat Oncol Biol Phys 58: 976-983
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.58
, pp. 976-983
-
-
Harari, P.M.1
Huang, S.M.2
-
56
-
-
0242442483
-
Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas
-
Li B, Chang CM, Yuan M, McKenna WG, Shu HK (2003) Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 63: 7443-7450
-
(2003)
Cancer Res
, vol.63
, pp. 7443-7450
-
-
Li, B.1
Chang, C.M.2
Yuan, M.3
McKenna, W.G.4
Shu, H.K.5
-
57
-
-
0642337954
-
EGF receptor as a therapeutic target: Patient selection and mechanisms of resistance to receptor-targeted drugs
-
Arteaga CL (2003) EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J Clin Oncol 21 (23 suppl): 289s-291s
-
(2003)
J Clin Oncol
, vol.21
, Issue.23 SUPPL.
-
-
Arteaga, C.L.1
-
58
-
-
0034114769
-
Blockade of receptors for growth factors: An anticancer therapy
-
Mendelsohn J (2000) Blockade of receptors for growth factors: an anticancer therapy. Clin Cancer Res 6: 747-753
-
(2000)
Clin Cancer Res
, vol.6
, pp. 747-753
-
-
Mendelsohn, J.1
-
59
-
-
0031409362
-
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
-
Mendelsohn J (1997) Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3: 2703-2707
-
(1997)
Clin Cancer Res
, vol.3
, pp. 2703-2707
-
-
Mendelsohn, J.1
-
60
-
-
0027428571
-
Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
-
Fan Z, Baselga J, Masui H, Mendelsohn J (1993) Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53: 4637-4642
-
(1993)
Cancer Res
, vol.53
, pp. 4637-4642
-
-
Fan, Z.1
Baselga, J.2
Masui, H.3
Mendelsohn, J.4
-
61
-
-
0027290650
-
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
-
Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, Mendelsohn J (1993) Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85: 1327-1333
-
(1993)
J Natl Cancer Inst
, vol.85
, pp. 1327-1333
-
-
Baselga, J.1
Norton, L.2
Masui, H.3
Pandiella, A.4
Coplan, K.5
Miller, W.H.6
Mendelsohn, J.7
-
62
-
-
0032904485
-
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
-
Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G (1999) Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5: 909-916
-
(1999)
Clin Cancer Res
, vol.5
, pp. 909-916
-
-
Ciardiello, F.1
Bianco, R.2
Damiano, V.3
De Lorenzo, S.4
Pepe, S.5
De Placido, S.6
Fan, Z.7
Mendelsohn, J.8
Bianco, A.R.9
Tortora, G.10
-
63
-
-
18844473781
-
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
-
Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R (2000) Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6: 1936-1948
-
(2000)
Clin Cancer Res
, vol.6
, pp. 1936-1948
-
-
Bruns, C.J.1
Harbison, M.T.2
Davis, D.W.3
Portera, C.A.4
Tsan, R.5
McConkey, D.J.6
Evans, D.B.7
Abbruzzese, J.L.8
Hicklin, D.J.9
Radinsky, R.10
-
64
-
-
0034489116
-
Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma
-
Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP (2000) Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6: 4874-4884
-
(2000)
Clin Cancer Res
, vol.6
, pp. 4874-4884
-
-
Inoue, K.1
Slaton, J.W.2
Perrotte, P.3
Davis, D.W.4
Bruns, C.J.5
Hicklin, D.J.6
McConkey, D.J.7
Sweeney, P.8
Radinsky, R.9
Dinney, C.P.10
-
65
-
-
0034084314
-
Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics and tumor angiogenesis
-
Huang S-M, Harari P (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesis. Clin Cancer Res 6: 2166-2174
-
(2000)
Clin Cancer Res
, vol.6
, pp. 2166-2174
-
-
Huang, S.-M.1
Harari, P.2
-
66
-
-
0032972944
-
Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
-
Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5: 257-265
-
(1999)
Clin Cancer Res
, vol.5
, pp. 257-265
-
-
Perrotte, P.1
Matsumoto, T.2
Inoue, K.3
Kuniyasu, H.4
Eve, B.Y.5
Hicklin, D.J.6
Radinsky, R.7
Dinney, C.P.8
-
67
-
-
0033818695
-
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells
-
Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Damiano V, De Lorenzo S, Pepe S et al (2000) Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6: 3739-3747
-
(2000)
Clin Cancer Res
, vol.6
, pp. 3739-3747
-
-
Ciardiello, F.1
Bianco, R.2
Damiano, V.3
Fontanini, G.4
Caputo, R.5
Pomatico, G.6
De Placido, S.7
Damiano, V.8
De Lorenzo, S.9
Pepe, S.10
-
68
-
-
0034068319
-
Antitumor effect and potentiation of cytotoxic drug activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor
-
Ciardiello F, Caputo R, Bianco R, Damiananco V, Pomatico G, De Placido S, Bianco AR, Tortora G (2000) Antitumor effect and potentiation of cytotoxic drug activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin Cancer Res 6: 2053-2063
-
(2000)
Clin Cancer Res
, vol.6
, pp. 2053-2063
-
-
Ciardiello, F.1
Caputo, R.2
Bianco, R.3
Damiananco, V.4
Pomatico, G.5
De Placido, S.6
Bianco, A.R.7
Tortora, G.8
-
69
-
-
0034896362
-
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
-
Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7: 1459-1465
-
(2001)
Clin Cancer Res
, vol.7
, pp. 1459-1465
-
-
Ciardiello, F.1
Caputo, R.2
Bianco, R.3
Damiano, V.4
Fontanini, G.5
Cuccato, S.6
De Placido, S.7
Bianco, A.R.8
Tortora, G.9
-
70
-
-
0000046996
-
ZD1839 ('Iressa') a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition
-
Woodburn JR, Kendrew J, Fennell M, Wakeling AE (2000) ZD1839 ('Iressa') a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition. Proc Am Assoc Cancer Res 41: 402
-
(2000)
Proc Am Assoc Cancer Res
, vol.41
, pp. 402
-
-
Woodburn, J.R.1
Kendrew, J.2
Fennell, M.3
Wakeling, A.E.4
-
71
-
-
0037399412
-
Tyrosine kinases as targets in cancer therapy - Successes and failures
-
Traxler P (2003) Tyrosine kinases as targets in cancer therapy - successes and failures. Expert Opin Ther Targets 7: 215-234
-
(2003)
Expert Opin Ther Targets
, vol.7
, pp. 215-234
-
-
Traxler, P.1
-
72
-
-
0034788453
-
Tyrosine kinase inhibitors: From rational design to clinical trials
-
Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J (2001) Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 21: 499-512
-
(2001)
Med Res Rev
, vol.21
, pp. 499-512
-
-
Traxler, P.1
Bold, G.2
Buchdunger, E.3
Caravatti, G.4
Furet, P.5
Manley, P.6
O'Reilly, T.7
Wood, J.8
Zimmermann, J.9
-
73
-
-
0038514987
-
Development of ZD1839 in colorectal cancer
-
Douglass EC (2003) Development of ZD1839 in colorectal cancer. Semin Oncol 30: 17-22
-
(2003)
Semin Oncol
, vol.30
, pp. 17-22
-
-
Douglass, E.C.1
-
74
-
-
0034489914
-
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa) an inhibitor of EGFR tyrosine kinase
-
Sirotnak FM, Zakowsky MF, Miller VA, Scher HI, Kris MG (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa) an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885-4892
-
(2000)
Clin Cancer Res
, vol.6
, pp. 4885-4892
-
-
Sirotnak, F.M.1
Zakowsky, M.F.2
Miller, V.A.3
Scher, H.I.4
Kris, M.G.5
-
75
-
-
0000238823
-
Low dose cisplatin can modulate the sensitivity of human non-small cell lung carcinoma cells to EGFR tyrosine kinase inhibitor (ZD1839; Iressa) in vivo
-
Ohmori T, Ao Y, Nishio K, Saijo N, Arteaga CL, Kurki T (2000) Low dose cisplatin can modulate the sensitivity of human non-small cell lung carcinoma cells to EGFR tyrosine kinase inhibitor (ZD1839; Iressa) in vivo. Proc Am Assoc Cancer Res 41: 482
-
(2000)
Proc Am Assoc Cancer Res
, vol.41
, pp. 482
-
-
Ohmori, T.1
Ao, Y.2
Nishio, K.3
Saijo, N.4
Arteaga, C.L.5
Kurki, T.6
-
77
-
-
0034788824
-
Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling
-
Harari PM, Huang SM (2001) Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 11: 281-289
-
(2001)
Semin Radiat Oncol
, vol.11
, pp. 281-289
-
-
Harari, P.M.1
Huang, S.M.2
-
78
-
-
0036570203
-
ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase
-
Hirata A, Ogawa S-I, Kometani T, Kuwano T, Naito S, Kuwano M, Ono M (2002) ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62: 2554-2560
-
(2002)
Cancer Res
, vol.62
, pp. 2554-2560
-
-
Hirata, A.1
Ogawa, S.-I.2
Kometani, T.3
Kuwano, T.4
Naito, S.5
Kuwano, M.6
Ono, M.7
-
79
-
-
0035674731
-
Oral administration of a novel taxane, an antisense oligonucelotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity
-
Tortora G, Caputo R, Damiano V, Fontanini G, Melisi D, Veneziani BM, Zunino F, Bianco AR, Ciardiello F (2001) Oral administration of a novel taxane, an antisense oligonucelotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clin Cancer Res 7: 4156-4163
-
(2001)
Clin Cancer Res
, vol.7
, pp. 4156-4163
-
-
Tortora, G.1
Caputo, R.2
Damiano, V.3
Fontanini, G.4
Melisi, D.5
Veneziani, B.M.6
Zunino, F.7
Bianco, A.R.8
Ciardiello, F.9
-
80
-
-
0037051103
-
Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD 1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo
-
Naruse I, Ohmori T, Ao Y, Fukumoto H, Kuroki T, Mori M, Saijo N, Nishio K (2002) Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD 1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 98: 310-315
-
(2002)
Int J Cancer
, vol.98
, pp. 310-315
-
-
Naruse, I.1
Ohmori, T.2
Ao, Y.3
Fukumoto, H.4
Kuroki, T.5
Mori, M.6
Saijo, N.7
Nishio, K.8
-
81
-
-
0001303066
-
Phase II trial of ZD1839 (Iressa), an EGF receptor inhibitor, in patients with advanced reanl cell carcinoma
-
2002: abstract 720
-
Drucker BJ, Schwartz L, Marion S, Motzer R (2002) Phase II trial of ZD1839 (Iressa), an EGF receptor inhibitor, in patients with advanced reanl cell carcinoma. Proc Am Soc Clin Oncol 2002: abstract 720
-
(2002)
Proc Am Soc Clin Oncol
-
-
Drucker, B.J.1
Schwartz, L.2
Marion, S.3
Motzer, R.4
-
82
-
-
0010276176
-
A phase I study ZD1839 (Iressa) in combination with oxaliplatin, 5-fluororuacil (5-FU) and leucovorin (LV) in advanced solid malignancies
-
2002: abstract 38
-
Cho CD, Fisher GA, Halsey JZ, Advani RH, Yuen AR, Sikic BI (2002) A phase I study ZD1839 (Iressa) in combination with oxaliplatin, 5-fluororuacil (5-FU) and leucovorin (LV) in advanced solid malignancies. Proc Am Soc Clin Oncol. 2002: abstract 38
-
(2002)
Proc Am Soc Clin Oncol
-
-
Cho, C.D.1
Fisher, G.A.2
Halsey, J.Z.3
Advani, R.H.4
Yuen, A.R.5
Sikic, B.I.6
-
83
-
-
0035174127
-
Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839
-
Albanell J, Rojo F, Baselga J (2001) Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol 28 (5 suppl 16): 56-66
-
(2001)
Semin Oncol
, vol.28
, Issue.5 SUPPL. 16
, pp. 56-66
-
-
Albanell, J.1
Rojo, F.2
Baselga, J.3
-
84
-
-
1242315578
-
Epidermal growth factor receptor inhibitors in clinical development
-
Dancey J (2004) Epidermal growth factor receptor inhibitors in clinical development. Int J Radiat Oncol Biol Phys 58: 1003-1007
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.58
, pp. 1003-1007
-
-
Dancey, J.1
-
85
-
-
0027339486
-
Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction
-
Modjtahedi H, Eccles S, Box G, Styles J, Dean C (1993) Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br J Cancer 67: 254-261
-
(1993)
Br J Cancer
, vol.67
, pp. 254-261
-
-
Modjtahedi, H.1
Eccles, S.2
Box, G.3
Styles, J.4
Dean, C.5
-
86
-
-
0002157402
-
Antitumour activity of rat Mabs to the human receptor for EGF
-
AA Epenetos, NR Lemonie (eds) Chapman and Hall, London
-
Modjtahedi H, Styles J, Box G, Eccles S, Gusterson B, Dean C (1993) Antitumour activity of rat Mabs to the human receptor for EGF. In: AA Epenetos, NR Lemonie (eds): Mutant oncogenes: targets for therapy? Chapman and Hall, London, 35-47
-
(1993)
Mutant Oncogenes: Targets for Therapy?
, pp. 35-47
-
-
Modjtahedi, H.1
Styles, J.2
Box, G.3
Eccles, S.4
Gusterson, B.5
Dean, C.6
-
87
-
-
0027265321
-
The growth response of human tumour cell lines expressing the EGF receptor to treatment with EGF and/or Mabs that block ligand binding
-
Modjtahedi H, Styles J, Dean C (1993) The growth response of human tumour cell lines expressing the EGF receptor to treatment with EGF and/or Mabs that block ligand binding. Int J Oncol 3: 237-243
-
(1993)
Int J Oncol
, vol.3
, pp. 237-243
-
-
Modjtahedi, H.1
Styles, J.2
Dean, C.3
-
88
-
-
0027428571
-
Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
-
Fan Z, Baselga J, Masui H, Mendelsohn J (1992) Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53: 4637-4642
-
(1992)
Cancer Res
, vol.53
, pp. 4637-4642
-
-
Fan, Z.1
Baselga, J.2
Masui, H.3
Mendelsohn, J.4
-
89
-
-
0032695910
-
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice
-
Pollack VA, Savage DM, Baker DA,Tsparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA et al (1999) Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291: 739-748
-
(1999)
J Pharmacol Exp Ther
, vol.291
, pp. 739-748
-
-
Pollack, V.A.1
Savage, D.M.2
Baker, D.A.3
Tsparikos, K.E.4
Sloan, D.E.5
Moyer, J.D.6
Barbacci, E.G.7
Pustilnik, L.R.8
Smolarek, T.A.9
Davis, J.A.10
-
90
-
-
0037838557
-
Development of the epidermal growth factor receptor inhibitor OSI-774
-
Grunwald V, Hidalgo M (2003) Development of the epidermal growth factor receptor inhibitor OSI-774. Semin Oncol 30: 23-31
-
(2003)
Semin Oncol
, vol.30
, pp. 23-31
-
-
Grunwald, V.1
Hidalgo, M.2
-
91
-
-
10844250444
-
Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with relotinib HCl (OSI-774) and chemotherapy: Subgroup analysis of TRIBUTE
-
2004: abstract 7061
-
Miller VA (2004) Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with relotinib HCl (OSI-774) and chemotherapy: subgroup analysis of TRIBUTE. Proc Am Soc Clin Oncol 2004: abstract 7061
-
(2004)
Proc Am Soc Clin Oncol
-
-
Miller, V.A.1
-
92
-
-
26044439215
-
Pharmacokinetic study of the phase III randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer
-
2004: abstract 2050
-
Tran HT (2004) Pharmacokinetic study of the phase III randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2004: abstract 2050
-
(2004)
Proc Am Soc Clin Oncol
-
-
Tran, H.T.1
-
93
-
-
0034951384
-
STI571: Targeting BCR-ABL as therapy for CML
-
Mauro MJ, Druker BJ (2001) STI571: targeting BCR-ABL as therapy for CML. Oncologist 6: 233-238
-
(2001)
Oncologist
, vol.6
, pp. 233-238
-
-
Mauro, M.J.1
Druker, B.J.2
-
94
-
-
0035344667
-
STI571: A gene product-targeted therapy for leukemia
-
Mauro MJ, Druker BJ (2001) STI571: a gene product-targeted therapy for leukemia. Curr Oncol Reports 3: 223-227
-
(2001)
Curr Oncol Reports
, vol.3
, pp. 223-227
-
-
Mauro, M.J.1
Druker, B.J.2
-
96
-
-
0035207448
-
The biology of signal transduction inhibition: Basic science to novel therapies
-
Griffin J (2001) The biology of signal transduction inhibition: basic science to novel therapies. Semin Oncol 28 (5 suppl 17): 3-8
-
(2001)
Semin Oncol
, vol.28
, Issue.5 SUPPL. 17
, pp. 3-8
-
-
Griffin, J.1
-
97
-
-
0036189039
-
STI571 (imatinib mesylate): The tale of a targeted therapy
-
Thambi P, Sausville EA (2002) STI571 (imatinib mesylate): the tale of a targeted therapy. Anti-Cancer Drugs 13: 111-114
-
(2002)
Anti-Cancer Drugs
, vol.13
, pp. 111-114
-
-
Thambi, P.1
Sausville, E.A.2
-
98
-
-
0037093061
-
Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogenic stem cell transplantation
-
Olavarria E, Craddock C, Dazzi F, Marin D, Marktel S, Apperley JF, Goldman JM (2002) Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogenic stem cell transplantation. Blood 99: 3861-3862
-
(2002)
Blood
, vol.99
, pp. 3861-3862
-
-
Olavarria, E.1
Craddock, C.2
Dazzi, F.3
Marin, D.4
Marktel, S.5
Apperley, J.F.6
Goldman, J.M.7
-
99
-
-
0036014978
-
Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia
-
Gorre ME, Sawyer CL (2002) Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 9: 303-307
-
(2002)
Curr Opin Hematol
, vol.9
, pp. 303-307
-
-
Gorre, M.E.1
Sawyer, C.L.2
-
100
-
-
0036179862
-
Recent advances in the treatment of chronic myelogenous leukemia
-
O'Dwyer ME, Mauro MJ, Druker BJ (2002) Recent advances in the treatment of chronic myelogenous leukemia. Annu Rev Med 53: 369-381
-
(2002)
Annu Rev Med
, vol.53
, pp. 369-381
-
-
O'Dwyer, M.E.1
Mauro, M.J.2
Druker, B.J.3
-
101
-
-
0036045378
-
Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: A translational perspective
-
La Rose P, O'Dwyer ME, Druker BJ (2002) Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 16: 1213-1219
-
(2002)
Leukemia
, vol.16
, pp. 1213-1219
-
-
La Rose, P.1
O'Dwyer, M.E.2
Druker, B.J.3
-
102
-
-
0037029731
-
The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukemia cells: Synergistic interactions with anti-leukemic agents
-
Liu WM, Stimson LA, Joel SP (2002) The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukemia cells: Synergistic interactions with anti-leukemic agents. Br J Cancer 86: 1472-1478
-
(2002)
Br J Cancer
, vol.86
, pp. 1472-1478
-
-
Liu, W.M.1
Stimson, L.A.2
Joel, S.P.3
-
103
-
-
0036159844
-
Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukemia
-
Marley SB, Davidson RJ, Goldman JM, Gordon MY (2002) Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukemia. Br J Hematol 116: 162-165
-
(2002)
Br J Hematol
, vol.116
, pp. 162-165
-
-
Marley, S.B.1
Davidson, R.J.2
Goldman, J.M.3
Gordon, M.Y.4
-
104
-
-
0242361680
-
Determination of drug synergism between the tyrosine kinase inhibitors NSC680410 (adaphostin) and/or STI571 (imatinib mesylaste, Gleevec) with cytotoxic drugs against human leukemia cell lines
-
Avramis IA, Laug WE, Sausville EA, Avramis VI (2003) Determination of drug synergism between the tyrosine kinase inhibitors NSC680410 (adaphostin) and/or STI571 (imatinib mesylaste, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother Pharmacol 52: 307-318
-
(2003)
Cancer Chemother Pharmacol
, vol.52
, pp. 307-318
-
-
Avramis, I.A.1
Laug, W.E.2
Sausville, E.A.3
Avramis, V.I.4
-
105
-
-
0037029687
-
Rationale for combination therapy of chronic myelogenous leukemia with imatinib and irradiation or alkylating agents: Implications for pretransplant conditioning
-
Topaly J, Fruehauf S, Ho AD, Zeller WJ (2002) Rationale for combination therapy of chronic myelogenous leukemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. Br J Cancer 86: 1487-1493
-
(2002)
Br J Cancer
, vol.86
, pp. 1487-1493
-
-
Topaly, J.1
Fruehauf, S.2
Ho, A.D.3
Zeller, W.J.4
-
106
-
-
0035525787
-
Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571
-
Wolff NC, Ilaria RL (2001) Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 98: 2808-2816
-
(2001)
Blood
, vol.98
, pp. 2808-2816
-
-
Wolff, N.C.1
Ilaria, R.L.2
-
107
-
-
0037188538
-
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9
-
Dash AB, Williams IR, Kutok JL, Tomasson MH, Anastasiadou E, Lindahl K, Li S, Van Etten RA, Borrow J, Housman D et al (2002) A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci USA 99: 7622-7627
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, pp. 7622-7627
-
-
Dash, A.B.1
Williams, I.R.2
Kutok, J.L.3
Tomasson, M.H.4
Anastasiadou, E.5
Lindahl, K.6
Li, S.7
Van Etten, R.A.8
Borrow, J.9
Housman, D.10
-
108
-
-
0035056924
-
Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents
-
Krystal GW (2001) Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents. Drug Resist Updat 4: 16-21
-
(2001)
Drug Resist Updat
, vol.4
, pp. 16-21
-
-
Krystal, G.W.1
-
109
-
-
0035328851
-
Indoline tyrosine kinase inhibitors block kit activation and growth of small cell lung cancer cells
-
Krystal GW, Honsawek S, Kiewlich D, Liang C, Vasile S, Sun L, McMahon G, Lipson KE (2001) Indoline tyrosine kinase inhibitors block kit activation and growth of small cell lung cancer cells. Cancer Res 61: 3660-3668
-
(2001)
Cancer Res
, vol.61
, pp. 3660-3668
-
-
Krystal, G.W.1
Honsawek, S.2
Kiewlich, D.3
Liang, C.4
Vasile, S.5
Sun, L.6
McMahon, G.7
Lipson, K.E.8
-
110
-
-
0035064790
-
Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients
-
Weisberg E, Griffin JD (2001) Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drug Resist Updat 4: 22-28
-
(2001)
Drug Resist Updat
, vol.4
, pp. 22-28
-
-
Weisberg, E.1
Griffin, J.D.2
-
111
-
-
9144234689
-
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
-
Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shisshodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M (2004) Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 64: 672-677
-
(2004)
Cancer Res
, vol.64
, pp. 672-677
-
-
Donato, N.J.1
Wu, J.Y.2
Stapley, J.3
Lin, H.4
Arlinghaus, R.5
Aggarwal, B.B.6
Shisshodia, S.7
Albitar, M.8
Hayes, K.9
Kantarjian, H.10
Talpaz, M.11
-
112
-
-
4644222221
-
SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resitance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)
-
2004: abstract 3001
-
Demetri GD (2004) SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resitance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2004: abstract 3001
-
(2004)
Proc Am Soc Clin Oncol
-
-
Demetri, G.D.1
-
113
-
-
0035211136
-
Targeting c-kit mutations in solid tumors: Scientific rationale and novel therapeutic options
-
Demetri GD (2001) Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 28 (5 suppl 17): 19-26
-
(2001)
Semin Oncol
, vol.28
, Issue.5 SUPPL. 17
, pp. 19-26
-
-
Demetri, G.D.1
-
114
-
-
0034785836
-
Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumors
-
Joensuu H, Dimitrijevic S (2001) Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumors. Ann Med 33: 451-455
-
(2001)
Ann Med
, vol.33
, pp. 451-455
-
-
Joensuu, H.1
Dimitrijevic, S.2
-
115
-
-
25044472752
-
Gastrointestinal stromal tumor (GIST) patients who respond to imatinib (STI571, Gleevec) show marked decline of circulating levels of VEGF, KIT, and bFGF in serum, but not stem cell factor (SCF) levels
-
2002: abstract 552
-
Joensuu H, Krause A, Demetri GD, Blanke C, von Mehren M, Heinrich MC, Eisenberg B, Roberts PJ, Silberman S, Dimitrijevic S et al (2002) Gastrointestinal stromal tumor (GIST) patients who respond to imatinib (STI571, Gleevec) show marked decline of circulating levels of VEGF, KIT, and bFGF in serum, but not stem cell factor (SCF) levels. Proc Am Soc Clin Oncol 2002: abstract 552
-
(2002)
Proc Am Soc Clin Oncol
-
-
Joensuu, H.1
Krause, A.2
Demetri, G.D.3
Blanke, C.4
Von Mehren, M.5
Heinrich, M.C.6
Eisenberg, B.7
Roberts, P.J.8
Silberman, S.9
Dimitrijevic, S.10
-
116
-
-
0037087531
-
Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies
-
Heinrich MC, Blanke CD, Druker BJ, Corlees CL (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20: 1692-1703
-
(2002)
J Clin Oncol
, vol.20
, pp. 1692-1703
-
-
Heinrich, M.C.1
Blanke, C.D.2
Druker, B.J.3
Corlees, C.L.4
-
117
-
-
8744288462
-
Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors: A review
-
Sawaki A, Yamao K (2004) Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors: a review. Cancer Chemotherap Pharmacol 54 (suppl 1): S44-S49
-
(2004)
Cancer Chemotherap Pharmacol
, vol.54
, Issue.SUPPL. 1
-
-
Sawaki, A.1
Yamao, K.2
-
118
-
-
0037150729
-
Recent advances in cancer research: Mouse models of tumorigenesis
-
Herzig M, Christofori G (2002) Recent advances in cancer research: mouse models of tumorigenesis. Biochim Biophys Acta 1602: 97-113
-
(2002)
Biochim Biophys Acta
, vol.1602
, pp. 97-113
-
-
Herzig, M.1
Christofori, G.2
-
119
-
-
0034787741
-
Spontaneous adenocarcinoma mouse models for immunotherapy
-
Gendler SJ, Mukherjee P (2001) Spontaneous adenocarcinoma mouse models for immunotherapy. Trends Mol Med 7: 471-475
-
(2001)
Trends Mol Med
, vol.7
, pp. 471-475
-
-
Gendler, S.J.1
Mukherjee, P.2
-
120
-
-
0034760178
-
New animal models to probe brain tumor biology, therapy, and immunotherapy: Advantages and remaining concerns
-
Lampson LA (2001) New animal models to probe brain tumor biology, therapy, and immunotherapy: advantages and remaining concerns. J Neurooncol 53: 275-287
-
(2001)
J Neurooncol
, vol.53
, pp. 275-287
-
-
Lampson, L.A.1
-
121
-
-
0036467484
-
Technologically advanced cancer modeling in mice
-
Tuveson DA, Jacks T (2002) Technologically advanced cancer modeling in mice. Curr Opin Genet Dev 12: 105-110
-
(2002)
Curr Opin Genet Dev
, vol.12
, pp. 105-110
-
-
Tuveson, D.A.1
Jacks, T.2
-
122
-
-
0037068352
-
Modeling cancer in mice
-
Jackson-Grusby L (2002) Modeling cancer in mice. Oncogene 21: 5504-5514
-
(2002)
Oncogene
, vol.21
, pp. 5504-5514
-
-
Jackson-Grusby, L.1
-
123
-
-
1542436704
-
Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans
-
Kerbel RS (2003) Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans. Cancer Biol Ther 2 (4 suppl 1): S134-S139
-
(2003)
Cancer Biol Ther
, vol.2
, Issue.4 SUPPL. 1
-
-
Kerbel, R.S.1
-
125
-
-
0347052797
-
Molecular aspects of epithelial cell plasticity: Implications for local tumor invasion and metastasis
-
Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug H, Mikulits W (2003) Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res 566: 9-20
-
(2003)
Mutat Res
, vol.566
, pp. 9-20
-
-
Gotzmann, J.1
Mikula, M.2
Eger, A.3
Schulte-Hermann, R.4
Foisner, R.5
Beug, H.6
Mikulits, W.7
-
126
-
-
0037302790
-
Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications
-
Chung LWK (2003) Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer 97 (3 suppl): 772-778
-
(2003)
Cancer
, vol.97
, Issue.3 SUPPL.
, pp. 772-778
-
-
Chung, L.W.K.1
-
127
-
-
0038488600
-
Clinical trial design for target specific anticancer agents
-
Hoekstra R, Verweij J, Eskens FALM (2003) Clinical trial design for target specific anticancer agents. Invest New Drugs 21: 243-250
-
(2003)
Invest New Drugs
, vol.21
, pp. 243-250
-
-
Hoekstra, R.1
Verweij, J.2
Eskens, F.A.L.M.3
|